Logo image of ACB

AURORA CANNABIS INC (ACB) Stock Fundamental Analysis

NASDAQ:ACB - Nasdaq - CA05156X8504 - Common Stock - Currency: USD

5.22  -0.12 (-2.25%)

After market: 5.22 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to ACB. ACB was compared to 198 industry peers in the Pharmaceuticals industry. ACB may be in some trouble as it scores bad on both profitability and health. ACB is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ACB was profitable.
In the past year ACB has reported a negative cash flow from operations.
In the past 5 years ACB always reported negative net income.
In the past 5 years ACB always reported negative operating cash flow.
ACB Yearly Net Income VS EBIT VS OCF VS FCFACB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1B -2B -3B

1.2 Ratios

ACB has a better Return On Assets (1.44%) than 83.84% of its industry peers.
ACB has a Return On Equity of 2.18%. This is amongst the best in the industry. ACB outperforms 84.34% of its industry peers.
Industry RankSector Rank
ROA 1.44%
ROE 2.18%
ROIC N/A
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
ACB Yearly ROA, ROE, ROICACB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200 -250

1.3 Margins

ACB has a better Profit Margin (3.90%) than 84.34% of its industry peers.
ACB's Gross Margin of 3.82% is in line compared to the rest of the industry. ACB outperforms 48.48% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 3.9%
GM 3.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACB Yearly Profit, Operating, Gross MarginsACB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

3

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ACB has been increased compared to 1 year ago.
The number of shares outstanding for ACB has been increased compared to 5 years ago.
ACB has a better debt/assets ratio than last year.
ACB Yearly Shares OutstandingACB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ACB Yearly Total Debt VS Total AssetsACB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

ACB has an Altman-Z score of -8.80. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.
ACB's Altman-Z score of -8.80 is on the low side compared to the rest of the industry. ACB is outperformed by 69.70% of its industry peers.
ACB has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
ACB has a Debt to Equity ratio (0.07) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -8.8
ROIC/WACCN/A
WACC8.72%
ACB Yearly LT Debt VS Equity VS FCFACB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 3.30 indicates that ACB has no problem at all paying its short term obligations.
The Current ratio of ACB (3.30) is comparable to the rest of the industry.
ACB has a Quick Ratio of 1.60. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of ACB (1.60) is worse than 61.11% of its industry peers.
Industry RankSector Rank
Current Ratio 3.3
Quick Ratio 1.6
ACB Yearly Current Assets VS Current LiabilitesACB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

ACB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 113.32%, which is quite impressive.
ACB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.92%.
ACB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.40% yearly.
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%

3.2 Future

The Earnings Per Share is expected to grow by 30.94% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACB will show a quite strong growth in Revenue. The Revenue will grow by 13.75% on average per year.
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue Next Year25.33%
Revenue Next 2Y18.21%
Revenue Next 3Y14.48%
Revenue Next 5Y13.75%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACB Yearly Revenue VS EstimatesACB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M
ACB Yearly EPS VS EstimatesACB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

ACB is valuated quite expensively with a Price/Earnings ratio of 32.63.
Compared to the rest of the industry, the Price/Earnings ratio of ACB indicates a rather cheap valuation: ACB is cheaper than 80.81% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ACB to the average of the S&P500 Index (26.03), we can say ACB is valued slightly more expensively.
The Price/Forward Earnings ratio is 21.46, which indicates a rather expensive current valuation of ACB.
Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than the industry average as 76.26% of the companies are valued more expensively.
ACB is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 21.94, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 32.63
Fwd PE 21.46
ACB Price Earnings VS Forward Price EarningsACB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACB Per share dataACB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ACB's earnings are expected to grow with 39.53% in the coming years.
PEG (NY)0.39
PEG (5Y)N/A
EPS Next 2Y55.4%
EPS Next 3Y39.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURORA CANNABIS INC

NASDAQ:ACB (5/21/2025, 8:00:00 PM)

After market: 5.22 0 (0%)

5.22

-0.12 (-2.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-05 2025-02-05/bmo
Earnings (Next)06-18 2025-06-18/amc
Inst Owners13.84%
Inst Owner Change64.91%
Ins Owners0.05%
Ins Owner ChangeN/A
Market Cap286.37M
Analysts74
Price Target7.64 (46.36%)
Short Float %9.45%
Short Ratio4.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2191.63%
Min EPS beat(2)-110.8%
Max EPS beat(2)4494.06%
EPS beat(4)2
Avg EPS beat(4)1134.64%
Min EPS beat(4)-110.8%
Max EPS beat(4)4494.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.22%
Min Revenue beat(2)13.79%
Max Revenue beat(2)14.66%
Revenue beat(4)3
Avg Revenue beat(4)7.53%
Min Revenue beat(4)-5.3%
Max Revenue beat(4)14.66%
Revenue beat(8)6
Avg Revenue beat(8)5.79%
Revenue beat(12)6
Avg Revenue beat(12)2.25%
Revenue beat(16)8
Avg Revenue beat(16)1.88%
PT rev (1m)4.37%
PT rev (3m)24.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)52.38%
EPS NY rev (1m)0%
EPS NY rev (3m)85.85%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.87%
Revenue NY rev (1m)-0.26%
Revenue NY rev (3m)6.62%
Valuation
Industry RankSector Rank
PE 32.63
Fwd PE 21.46
P/S 1.25
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.82
EV/EBITDA N/A
EPS(TTM)0.16
EY3.07%
EPS(NY)0.24
Fwd EY4.66%
FCF(TTM)-0.38
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS4.18
BVpS7.49
TBVpS6.35
PEG (NY)0.39
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.44%
ROE 2.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 3.9%
GM 3.82%
FCFM N/A
ROA(3y)-64.28%
ROA(5y)-63.23%
ROE(3y)-101.76%
ROE(5y)-92.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.17%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.3
Quick Ratio 1.6
Altman-Z -8.8
F-Score6
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)46.6%
Cap/Depr(5y)183.64%
Cap/Sales(3y)14.16%
Cap/Sales(5y)67.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)113.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%216%
EPS Next Y84.56%
EPS Next 2Y55.4%
EPS Next 3Y39.53%
EPS Next 5Y30.94%
Revenue 1Y (TTM)19.92%
Revenue growth 3Y-1.04%
Revenue growth 5Y37.4%
Sales Q2Q%36.91%
Revenue Next Year25.33%
Revenue Next 2Y18.21%
Revenue Next 3Y14.48%
Revenue Next 5Y13.75%
EBIT growth 1Y7.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year210.19%
EBIT Next 3Y52.94%
EBIT Next 5Y31.71%
FCF growth 1Y80.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y93.36%
OCF growth 3YN/A
OCF growth 5YN/A